KIR3DL1 and type 1 diabetes mellitus: To validate those findings, we recruited 10 T1D patients (including new onset T1D patients and individuals with long standing disease) and 10 matched healthy controls and performed KIR immunophenotyping of CD4+, CD8+ and NK cell subsets by flow cytometry (see Materials and methods).